AstraZeneca’s senior vice-president and head of precision medicine, research & development, Ruth March, has been central to the company’s transformed approach to personalised treatment.
We are in the most competitive period ever for the pharmaceutical industry, characterised by incremental innovation and looming patent cliffs – and path-to-market strategy firm IDEA Pharma
Johnson & Johnson’s global head of external innovation, William 'Bill' Hait, describes innovation as often being “an overnight success you’ve worked on for many years”.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.